Intraperitoneal enalapril ameliorates morphologic changes induced by hypertonic peritoneal dialysis solutions in rat peritoneum.

Soner Duman, Katarzyna Wieczorowska-Tobis, Arkadiusz Styszynski, Beata Kwiatkowska, Andrzej Breborowicz, Dimitrios G. Oreopoulos

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Peritoneal fibrosis (PF) is one of the most serious causes of technique failure in long-term peritoneal dialysis (PD). Although the mechanisms responsible for the genesis of PF are not well understood, angiotensin II is known to promote fibrosis and inflammation in various tissues and angiotensin converting enzyme inhibitors (ACEIs) have been shown to attenuate those effects. We previously showed that ACEIs have beneficial effects on peritoneal alterations induced by hypertonic (3.86% glucose) PD solutions. In the present study, we investigated the local effects of intraperitoneal (IP) enalapril on peritoneal alterations induced by 3.86% glucose PD solution in rats on chronic PD. One week after peritoneal catheter insertion, 23 non uremic male rats were randomly divided into two groups: group A (n = 11) received 20 mL 3.86% PD solution twice daily, and group B (n = 12) received 20 mL 3.86% PD solution containing 1 mg/L enalapril twice daily. After 4 weeks of such infusions, we measured net ultrafiltration (UF) volume and obtained samples of visceral peritoneum from the liver for thickness measurement. Net UF was significantly higher (6.6 +/- 0.2 mL vs. 5.6 +/- 0.2 mL) and peritoneal thickness was significantly lower (30 +/- 5 microm vs. 52 +/- 0.8 microm) in group B. We conclude that intraperitoneal enalapril (an ACEI) protects the peritoneal membrane from the effects of hypertonic glucose. This protection might be mediated by enalapril's interference with angiotensin though inhibition of cytokine overexpression.

Original languageEnglish (US)
Pages (from-to)31-36
Number of pages6
JournalAdvances in peritoneal dialysis. Conference on Peritoneal Dialysis
Volume20
StatePublished - 2004
Externally publishedYes

Fingerprint

Enalapril
Peritoneum
Dialysis Solutions
Peritoneal Dialysis
Peritoneal Fibrosis
Angiotensin-Converting Enzyme Inhibitors
Ultrafiltration
Glucose
Angiotensins
Angiotensin II
Fibrosis
Catheters
Cytokines
Inflammation
Membranes
Liver

Cite this

Intraperitoneal enalapril ameliorates morphologic changes induced by hypertonic peritoneal dialysis solutions in rat peritoneum. / Duman, Soner; Wieczorowska-Tobis, Katarzyna; Styszynski, Arkadiusz; Kwiatkowska, Beata; Breborowicz, Andrzej; Oreopoulos, Dimitrios G.

In: Advances in peritoneal dialysis. Conference on Peritoneal Dialysis, Vol. 20, 2004, p. 31-36.

Research output: Contribution to journalArticle

Duman, Soner ; Wieczorowska-Tobis, Katarzyna ; Styszynski, Arkadiusz ; Kwiatkowska, Beata ; Breborowicz, Andrzej ; Oreopoulos, Dimitrios G. / Intraperitoneal enalapril ameliorates morphologic changes induced by hypertonic peritoneal dialysis solutions in rat peritoneum. In: Advances in peritoneal dialysis. Conference on Peritoneal Dialysis. 2004 ; Vol. 20. pp. 31-36.
@article{0e3667cbc85648e7bbde7d721d17eb25,
title = "Intraperitoneal enalapril ameliorates morphologic changes induced by hypertonic peritoneal dialysis solutions in rat peritoneum.",
abstract = "Peritoneal fibrosis (PF) is one of the most serious causes of technique failure in long-term peritoneal dialysis (PD). Although the mechanisms responsible for the genesis of PF are not well understood, angiotensin II is known to promote fibrosis and inflammation in various tissues and angiotensin converting enzyme inhibitors (ACEIs) have been shown to attenuate those effects. We previously showed that ACEIs have beneficial effects on peritoneal alterations induced by hypertonic (3.86{\%} glucose) PD solutions. In the present study, we investigated the local effects of intraperitoneal (IP) enalapril on peritoneal alterations induced by 3.86{\%} glucose PD solution in rats on chronic PD. One week after peritoneal catheter insertion, 23 non uremic male rats were randomly divided into two groups: group A (n = 11) received 20 mL 3.86{\%} PD solution twice daily, and group B (n = 12) received 20 mL 3.86{\%} PD solution containing 1 mg/L enalapril twice daily. After 4 weeks of such infusions, we measured net ultrafiltration (UF) volume and obtained samples of visceral peritoneum from the liver for thickness measurement. Net UF was significantly higher (6.6 +/- 0.2 mL vs. 5.6 +/- 0.2 mL) and peritoneal thickness was significantly lower (30 +/- 5 microm vs. 52 +/- 0.8 microm) in group B. We conclude that intraperitoneal enalapril (an ACEI) protects the peritoneal membrane from the effects of hypertonic glucose. This protection might be mediated by enalapril's interference with angiotensin though inhibition of cytokine overexpression.",
author = "Soner Duman and Katarzyna Wieczorowska-Tobis and Arkadiusz Styszynski and Beata Kwiatkowska and Andrzej Breborowicz and Oreopoulos, {Dimitrios G.}",
year = "2004",
language = "English (US)",
volume = "20",
pages = "31--36",
journal = "Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.",
issn = "1197-8554",
publisher = "Peritoneal Dialysis Bulletin",

}

TY - JOUR

T1 - Intraperitoneal enalapril ameliorates morphologic changes induced by hypertonic peritoneal dialysis solutions in rat peritoneum.

AU - Duman, Soner

AU - Wieczorowska-Tobis, Katarzyna

AU - Styszynski, Arkadiusz

AU - Kwiatkowska, Beata

AU - Breborowicz, Andrzej

AU - Oreopoulos, Dimitrios G.

PY - 2004

Y1 - 2004

N2 - Peritoneal fibrosis (PF) is one of the most serious causes of technique failure in long-term peritoneal dialysis (PD). Although the mechanisms responsible for the genesis of PF are not well understood, angiotensin II is known to promote fibrosis and inflammation in various tissues and angiotensin converting enzyme inhibitors (ACEIs) have been shown to attenuate those effects. We previously showed that ACEIs have beneficial effects on peritoneal alterations induced by hypertonic (3.86% glucose) PD solutions. In the present study, we investigated the local effects of intraperitoneal (IP) enalapril on peritoneal alterations induced by 3.86% glucose PD solution in rats on chronic PD. One week after peritoneal catheter insertion, 23 non uremic male rats were randomly divided into two groups: group A (n = 11) received 20 mL 3.86% PD solution twice daily, and group B (n = 12) received 20 mL 3.86% PD solution containing 1 mg/L enalapril twice daily. After 4 weeks of such infusions, we measured net ultrafiltration (UF) volume and obtained samples of visceral peritoneum from the liver for thickness measurement. Net UF was significantly higher (6.6 +/- 0.2 mL vs. 5.6 +/- 0.2 mL) and peritoneal thickness was significantly lower (30 +/- 5 microm vs. 52 +/- 0.8 microm) in group B. We conclude that intraperitoneal enalapril (an ACEI) protects the peritoneal membrane from the effects of hypertonic glucose. This protection might be mediated by enalapril's interference with angiotensin though inhibition of cytokine overexpression.

AB - Peritoneal fibrosis (PF) is one of the most serious causes of technique failure in long-term peritoneal dialysis (PD). Although the mechanisms responsible for the genesis of PF are not well understood, angiotensin II is known to promote fibrosis and inflammation in various tissues and angiotensin converting enzyme inhibitors (ACEIs) have been shown to attenuate those effects. We previously showed that ACEIs have beneficial effects on peritoneal alterations induced by hypertonic (3.86% glucose) PD solutions. In the present study, we investigated the local effects of intraperitoneal (IP) enalapril on peritoneal alterations induced by 3.86% glucose PD solution in rats on chronic PD. One week after peritoneal catheter insertion, 23 non uremic male rats were randomly divided into two groups: group A (n = 11) received 20 mL 3.86% PD solution twice daily, and group B (n = 12) received 20 mL 3.86% PD solution containing 1 mg/L enalapril twice daily. After 4 weeks of such infusions, we measured net ultrafiltration (UF) volume and obtained samples of visceral peritoneum from the liver for thickness measurement. Net UF was significantly higher (6.6 +/- 0.2 mL vs. 5.6 +/- 0.2 mL) and peritoneal thickness was significantly lower (30 +/- 5 microm vs. 52 +/- 0.8 microm) in group B. We conclude that intraperitoneal enalapril (an ACEI) protects the peritoneal membrane from the effects of hypertonic glucose. This protection might be mediated by enalapril's interference with angiotensin though inhibition of cytokine overexpression.

UR - http://www.scopus.com/inward/record.url?scp=7044222845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7044222845&partnerID=8YFLogxK

M3 - Article

C2 - 15384791

AN - SCOPUS:7044222845

VL - 20

SP - 31

EP - 36

JO - Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

JF - Advances in peritoneal dialysis. Conference on Peritoneal Dialysis.

SN - 1197-8554

ER -